<DOC>
	<DOCNO>NCT00909441</DOCNO>
	<brief_summary>Title Study : Sentinel node biopsy follow neoadjuvant chemotherapy biopsy proven node positive breast cancer . Objectives study : Primary objective 1 . Evaluate accuracy sentinel node biopsy breast cancer patient present positive nodal disease , proven ultrasound guide fine needle aspiration , follow neoadjuvant chemotherapy . Secondary objective 1 . Evaluate technical success sentinel node biopsy follow neoadjuvant chemotherapy . 2 . Evaluate accuracy clinical examination ultrasound examination axilla identify presence residual disease axilla follow neoadjuvant chemotherapy biopsy proven node positive breast cancer patient . Number patient : N = 300 Population : Patients unresected breast cancer eligible neoadjuvant chemotherapy present biopsy proven positive axillary node . Study duration : From February 2009 February 2012 - 3 year</brief_summary>
	<brief_title>Sentinel Node Biopsy Following NeoAdjuvant Chemotherapy Biopsy Proven Node Positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Conditions patient eligibility Inclusion criterion : Patients must female . Patients must 18 year age old . Patients stage IIA , IIB , IIIA ( T13 N12 ) breast cancer . Clinical N0 accept biopsy proven node disease . Patients biopsy proven positive axillary disease make core needle biopsy fine needle aspiration . Patients accept undergo neoadjuvant chemotherapy ; patient eligible day surgery . Patients bilateral breast cancer eligible . Sentinel node biopsy allow contralateral breast disease axilla prior chemotherapy . Patients understand , accept sign approved consent form . Patients inflammatory breast cancer . Patient stage IIIB , IIIC IV breast cancer ( T4 N3 ) Patients clinical N3 disease exclude . Patients previous axillary dissection axillary sentinel node biopsy ; ( patient excisional biopsy ipsilateral tumorectomy eligible ) . Patients previous radiotherapy axillary node Patients mammary reduction Patients medically unfit receive chemotherapy , evaluate treat physician . If injection blue dye plan , patient hypersensitivity allergy isosulfan blue , Patent blue methylene blue radiocolloid dye ineligible . Patients pregnant breast feed . Psychiatric addictive disorder condition preclude patient meeting study requirement .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Node Positive Breast Cancer</keyword>
	<keyword>Sentinel Lymph Node Biopsy</keyword>
	<keyword>Breast Surgery</keyword>
	<keyword>Axillary Lymph Node Dissection</keyword>
	<keyword>Neoadjuvant Chemotherapy</keyword>
</DOC>